Theravance Biopharma, Inc. Quarterly Stockholders' Equity Attributable to Parent in USD from Q4 2011 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
Summary
Theravance Biopharma, Inc. quarterly Stockholders' Equity Attributable to Parent history and growth rate from Q4 2011 to Q2 2024.
  • Theravance Biopharma, Inc. Stockholders' Equity Attributable to Parent for the quarter ending June 30, 2024 was $194M, a 30.9% decline year-over-year.
Stockholders' Equity Attributable to Parent, Quarterly (USD)
Stockholders' Equity Attributable to Parent, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $194M -$86.5M -30.9% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $205M -$166M -44.7% Mar 31, 2024 10-Q 2024-08-08
Q4 2023 $213M -$229M -51.8% Dec 31, 2023 10-Q 2024-08-08
Q3 2023 $246M -$234M -48.8% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $280M +$630M Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $371M +$722M Mar 31, 2023 10-Q 2024-08-08
Q4 2022 $442M +$780M Dec 31, 2022 10-Q 2024-08-08
Q3 2022 $481M +$804M Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$350M -$49.4M -16.5% Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$351M +$21.8M +5.83% Mar 31, 2022 10-Q 2023-08-09
Q4 2021 -$339M -$34.8M -11.5% Dec 31, 2021 10-K 2024-03-01
Q3 2021 -$324M -$62.1M -23.7% Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$300M -$98M -48.5% Jun 30, 2021 10-Q 2022-11-09
Q1 2021 -$373M -$215M -136% Mar 31, 2021 10-Q 2022-08-08
Q4 2020 -$304M -$79.9M -35.7% Dec 31, 2020 10-K 2023-03-01
Q3 2020 -$262M -$78.7M -43.1% Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$202M -$65.1M -47.4% Jun 30, 2020 10-Q 2021-11-08
Q1 2020 -$158M -$44.7M -39.5% Mar 31, 2020 10-Q 2021-08-05
Q4 2019 -$224M -$172M -334% Dec 31, 2019 10-K 2023-03-01
Q3 2019 -$183M -$169M -1260% Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$137M -$172M -499% Jun 30, 2019 10-Q 2020-11-09
Q1 2019 -$113M -$177M -279% Mar 31, 2019 10-Q 2020-08-10
Q4 2018 -$51.6M -$167M -145% Dec 31, 2018 10-K 2022-02-28
Q3 2018 -$13.4M -$198M -107% Sep 30, 2018 10-Q 2019-11-08
Q2 2018 $34.4M -$207M -85.7% Jun 30, 2018 10-Q 2019-11-08
Q1 2018 $63.4M -$231M -78.4% Mar 31, 2018 10-Q 2019-08-05
Q4 2017 $115M -$235M -67.1% Dec 31, 2017 10-K 2021-02-26
Q3 2017 $184M -$114M -38.2% Sep 30, 2017 10-Q 2017-11-08
Q2 2017 $241M -$80.5M -25% Jun 30, 2017 10-Q 2017-08-09
Q1 2017 $294M +$55.4M +23.2% Mar 31, 2017 10-Q 2017-05-10
Q4 2016 $350M +$107M +44.1% Dec 31, 2016 10-K 2020-02-27
Q3 2016 $298M +$75.3M +33.8% Sep 30, 2016 10-Q 2016-11-09
Q2 2016 $322M +$63.9M +24.8% Jun 30, 2016 10-Q 2016-08-09
Q1 2016 $239M -$50.6M -17.5% Mar 31, 2016 10-Q 2016-05-10
Q4 2015 $243M -$46.7M -16.1% Dec 31, 2015 10-K 2019-02-28
Q3 2015 $223M -$117M -34.5% Sep 30, 2015 10-Q 2015-11-12
Q2 2015 $258M -$127M -33% Jun 30, 2015 10-Q 2015-08-13
Q1 2015 $289M +$307M Mar 31, 2015 10-Q 2015-05-13
Q4 2014 $290M +$307M Dec 31, 2014 10-K 2018-02-28
Q3 2014 $340M Sep 30, 2014 10-Q 2014-11-12
Q2 2014 $385M Jun 30, 2014 10-Q 2014-08-14
Q1 2014 -$17.9M Mar 31, 2014 10-Q 2014-06-24
Q4 2013 -$17M -$10M -144% Dec 31, 2013 10-K 2017-03-01
Q4 2012 -$6.99M +$134M +95% Dec 31, 2012 10-K 2016-03-11
Q4 2011 -$141M Dec 31, 2011 10-K 2015-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.